Search research articles
Contact Us
Filters
Showing results (311-320 of 455) with videos related to
Page
of 46
Sort By:
BMJ Open
|
January 10, 2014
Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
Pelle L Ishøy, Filip K Knop, Brian V Broberg, et al.
Journal of the American Heart Association
|
October 26, 2020
High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial
Kasper M Petersen, Søren Bøgevig, Troels Riis, et al.
Nephron
|
October 26, 2020
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis
Tobias Bomholt, Thomas Idorn, Filip K Knop, et al.
European Journal of Endocrinology
|
January 15, 2021
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes
Niels B Dalsgaard, Lærke S Gasbjerg, Laura S Hansen, et al.
Scientific Reports
|
September 9, 2024
Transcutaneous vagus nerve stimulation has no anti-inflammatory effect in diabetes
Tina Okdahl, Huda Kufaishi, Ditte Kornum, et al.
American Journal of Preventive Cardiology
|
June 15, 2026
Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE - primary prevention study
Kim G Smolderen, Carlos Mena-Hurtado, Victoria Divino, et al.
Diabetes Care
|
April 3, 2019
Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts
Yuki M F Andersen, Alexander Egeberg, Lu Ban, et al.
Diabetes, Obesity & Metabolism
|
December 27, 2023
Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer
Henriette H Nerild, Andreas Brønden, Abdullah E Haddouchi, et al.
Endocrine Connections
|
November 10, 2023
Hyperglucagonaemia and amino acid alterations in individuals with type 2 diabetes and non-alcoholic fatty liver disease
Iben Rix, Marie L Johansen, Asger Lund, et al.
Lancet (London, England)
|
March 22, 2026
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
Jeffrey L Cummings, Alireza Atri, Mary Sano, et al.
Page
of 46
Search research articles
Search
Showing results (311-320 of 455) with videos related to
Sort By:
Page
of 46
BMJ Open
|
January 10, 2014
Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
Pelle L Ishøy, Filip K Knop, Brian V Broberg, et al.
Journal of the American Heart Association
|
October 26, 2020
High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial
Kasper M Petersen, Søren Bøgevig, Troels Riis, et al.
Nephron
|
October 26, 2020
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis
Tobias Bomholt, Thomas Idorn, Filip K Knop, et al.
European Journal of Endocrinology
|
January 15, 2021
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes
Niels B Dalsgaard, Lærke S Gasbjerg, Laura S Hansen, et al.
Scientific Reports
|
September 9, 2024
Transcutaneous vagus nerve stimulation has no anti-inflammatory effect in diabetes
Tina Okdahl, Huda Kufaishi, Ditte Kornum, et al.
American Journal of Preventive Cardiology
|
June 15, 2026
Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE - primary prevention study
Kim G Smolderen, Carlos Mena-Hurtado, Victoria Divino, et al.
Diabetes Care
|
April 3, 2019
Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts
Yuki M F Andersen, Alexander Egeberg, Lu Ban, et al.
Diabetes, Obesity & Metabolism
|
December 27, 2023
Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer
Henriette H Nerild, Andreas Brønden, Abdullah E Haddouchi, et al.
Endocrine Connections
|
November 10, 2023
Hyperglucagonaemia and amino acid alterations in individuals with type 2 diabetes and non-alcoholic fatty liver disease
Iben Rix, Marie L Johansen, Asger Lund, et al.
Lancet (London, England)
|
March 22, 2026
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
Jeffrey L Cummings, Alireza Atri, Mary Sano, et al.
Page
of 46